SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as investors brace for earnings, with the community debating whether the report will justify the stock's high valuation amid broader AI sector scrutiny. Concerns about insider selling and potential market overreaction are also fueling discussions, even with anticipation for a long-term bullish outlook following the report. Overall, sentiment is mixed as traders assess whether a beat is already priced in or if positive guidance can propel further gains.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending amid optimism surrounding deep-sea mining prospects and potential government involvement, with the CEO heading back to Washington. Community members are discussing the possibility of government stakes and key partnerships, especially with rising geopolitical tensions and the need for non-Chinese sourced minerals. Bullish sentiment seems to be fueled by the potential for significant long-term growth in the critical minerals sector.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending due to an increased share repurchase program, authorized up to $35 million, sparking community debate about its impact. While some view the buyback as a positive signal of confidence before commercialization milestones, others question the timing given previous share dilutions and the CEO's history. Discussions also include the potential for revenue growth from Tonmya and analyst projections.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

EOSE is trending due to a recent order from Frontier Power, viewed as validation after a short seller report, and community members are actively discussing the stock's valuation, its potential role in energy storage for AI data centers, and implications of warrant expirations. The community is also debating the impact of a registered direct offering and private placement on the company's balance sheet and future prospects, with some expressing concerns about dilution while others see it as a strategic move to fund expansion.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media is trending amid community discussion around the impending release of Epstein files and speculation about potential connections to prominent figures.  The community is divided, with some alleging a targeted attack against certain individuals, while others demand full transparency. Broader discussions encompass political affiliations and potential impacts on the stock.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss recent insider buying and the potential award of a major NASA contract for a lunar terrain vehicle (LTV). The community is weighing the significance of the insider purchase, speculating it signals confidence in securing the LTV contract, while others analyze chart patterns and potential near-term price movements amid market volatility.

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company, which engages in the business of pharmaceutical drug development. It focuses on its Paxalisib program, which is designed to treat brain cancer. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Kazia Therapeutics Limited - ADR

Kazia Therapeutics

KZIA is trending due to promising early data from a Phase 1b trial for triple-negative breast cancer, showing a significant reduction in tumor cells. The community is actively discussing the potential for a short squeeze given the low float and high short interest, while also weighing the possibility of a near-term offering. Some investors are optimistic about the drug's potential impact on cancer treatment and are anticipating further data releases.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending due to positive data from a Roche breast cancer trial, which has boosted optimism around Olema's similar treatment and sparked significant volatility. The community is discussing the potential for a short squeeze and a possible offering, with some analysts raising price targets significantly. Some traders express caution due to the lack of direct news from OLMA and the high percentage increase, suggesting a potential pump and dump.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Strike Coin

Starknet ($STRK) is trending as discussions surge around its potential to scale Bitcoin through BTCFi incentives and zk rollup technology. The community is focused on the increasing amount of staked $STRK and $BTC on the platform, alongside the improved efficiency and lower fees resulting from recent upgrades. Some analysts suggest Starknet's advancements position it to significantly benefit from Ethereum's upcoming Dencun upgrade, attracting attention as a layer-2 solution.

Nutex Health, Inc. engages in the management and operation of healthcare facilities. It operates through the following segments: Hospital Division, Population Health Management Division, and Real State Division. The Hospital Division is involved in developing and operating a network of micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). The Population Health Division establishes and operates provider networks such as independent physician associations (IPAs). The Real State Division owns land and hospital buildings which are leased to hospital entities. The company was founded in 2011 and is headquartered in Houston, TX.

Nutex Health Inc

Nutex Health ($NUTX) is trending due to community discussion around a potential short squeeze, with traders pointing to a significant short position held by Blue Orca and anticipating a price surge as shorts are forced to cover. Some investors are also awaiting upcoming earnings reports and financial restatements, expecting positive results to further drive the stock's momentum. The community is actively monitoring trading volumes and technical indicators, speculating on potential breakout points and resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.<a href="https://stocktwits.com/symbol/SONN">SONN shares</a> were trading 82% higher on Monday afternoon at the time of writing.At the closing of the transaction, the newly-created entity is to be named Hyperliquid Strategies Inc. (HSI), which is expected to hold approximately 12.6 million HYPE tokens, representing $583 million in value shortly before agreement signing and gross cash invested of at least $305 million, for a total assumed closing value of $888 million.The gross cash proceeds of $305 million at closing will enable HSI to acquire significantly more HYPE, creating one of the top strategic reserves of the HYPE token, the company said.HSI is expected to remain listed on the Nasdaq under a new ticker symbol and become a public cryptocurrency treasury company upon the closing of the transaction.Sonnet will operate as a wholly-owned subsidiary of HSI and will continue focusing on existing assets and business lines, including the development of its investigational cancer drug SON-1010, while disposing of other assets.Bob Diamond, co-founder and CEO of Atlas Merchant Capital LLC, will be named Chairman of the Board, and David Schamis, CIO and Co-founder of Atlas, will be named Chief Executive Officer of HSI.It is expected that current owners of Rorschach and other new investors at closing will own approximately 98.8% of HSI, and the legacy stockholders of SONN will own the remaining approximately 1.2%.Raghu Rao, interim CEO of Sonnet, said that with the transaction, the company will be able to capitalize on the recent advancements around digital assets and equip Sonnet with funding to potentially realize the future value of its existing biotech assets.Sonnet will also raise an aggregate $5.5 million in a private placement as part of the agreement, which is expected to close on July 14.The business combination agreement is now subject to approval by Sonnet stockholders and other customary closing conditions. The closing of the business combination is expected to occur in the second half of this year.On Stocktwits, retail sentiment around Sonnet is unchanged within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_2_14_50_PM_png_b81036dcad.webp" alt="SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>SONN's Sentiment Meter and Message Volume as of 2:15 p.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>SONN stock is up by 545% this year and by 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-transfers-portion-of-holdings-to-ex-wife-as-part-of-divorce-settlement/ch893xvR5nB">Rivian CEO Transfers Portion Of Holdings In EV Maker To Ex-Wife As Part Of Divorce Settlement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Sonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays Exuberant

Shares of Sonnet BioTherapeutics, Inc. (SONN) soared on Monday after the company entered a definitive business combination agreement with Rorschach I LLC to build a reserve of HYPE

Equity

At the closing of the transaction, the newly created combined entity will be named Hyperliquid Strategies Inc., which is expected to hold approximately 12.6 million HYPE tokens.

Sonnet BioTherapeutics Advances SON-080 into Phase 2 Trials

Sonnet BioTherapeutics Holdings (SONN) just unveiled an update. Promising results from the Phase 1b trial of SON-080 for chemotherapy-induced perip...

Sonnet BioTherapeutics to Present Preclinical Data on SON-080 for Chemotherapy-Induced Peripheral Neuropathy (CIPN) at the AACR 2024 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / March 19, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ('Sonnet' or the 'Company'), a biopharmaceutical company developing innovative targeted biologic...

Sonnet BioTherapeutics Announces Early Safety Data from the Company's Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study's Initial Pre-Specified Objective

Safety in the Phase 1b part of Sonnet's double-blind, randomized, controlled trial of SON-080 was reviewed by the study's Data Safety Monitoring Board (DSMB)The adverse event profile and tolerability...

Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers

PRINCETON, NJ / ACCESSWIRE / February 29, 2024 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today...

Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update

Successfully raised approximately $4.55 million in gross proceeds through an underwritten public offeringExtensive preclinical data on SON-1210 published in Frontiers in ImmunologyReceived approval...

BTIG Reaffirms Their Buy Rating on Sonnet BioTherapeutics Holdings (SONN)

BTIG analyst Kaveri Pohlman maintained a Buy rating on Sonnet BioTherapeutics Holdings (SONN Research Report) on January 5 and set a price target...

This account has been verified as an official SONN representative.

Verified Account

Sonnet Biotherapeutics

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. It focuses on Fully Human Albumin Binding (FHAB) technology which utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

SONN
Sonnet BioTherapeutics Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results:

Historical Earnings

Latest SONN News

SONNSonnet BioTherapeutics Holdings Inc